INTRODUCING WIXELA® INHUB® – DESIGNED TO ENABLE A SEAMLESS TRANSITION FROM ADVAIR® DISKUS®
Mylan is proud to announce that Wixela Inhub is now listed on the Ontario Drug Benefit Formulary as an interchangeable benefit effective March 31, 2020. READ MORE
WIXELA and INHUB are registered trademarks of Mylan Pharmaceuticals ULC.
ADVAIR and DISKUS are registered trademarks of Glaxo Group Limited.
Now available and eligible for reimbursement in BC, AB, MB, NB, NS, ON, QC and SK upon meeting certain criteria. Please visit the respective provincial formularies to view the exact criteria. Movapo patient support program also available. READ MORE
DISCOVER THE LATEST ADVANCES IN BIOLOGIC TREATMENT FOR PSORIASIS
Learn the fundamentals: Why they work. How they’re given. Where they fit. READ MORE
PRODUCT AWARENESS
PENTASA® AVAILABLE IN ORAL AND RECTAL FORMATS
PENTASA® is available in three distinct dosing forms. Consider PENTASA® for appropriate mild-to-moderate ulcerative colitis patients, and refer to the PENTASA® Product Monograph for further information. READ MORE
PRESERVATIVE-FREE DRY EYE RELIEF
Soothe® Night Time ophthalmic ointment provides temporary relief of dry eye. Comes in a convenient tube with built-in applicator tip. READ MORE
